Delving into the Latest Updates on Magnesium citrate with Synapse

Overview

Basic Info

SummaryMagnesium citrate is a type of small molecule drug that is a combination of magnesium and citric acid in a 1:1 ratio. It is approved for use in the exclusion of intestinal contents during colon examination and as a pretreatment laxative for abdominal surgery. Magnesium citrate is available under the trade names Magcorol and Tectlol. The drug is manufactured by RMJ Holdings and was first approved in Japan on April 28, 1973. Magnesium citrate works by attracting water to the intestine and promoting bowel movement, thus clearing the intestinal tract. It is commonly used for bowel preparation prior to colonoscopy or other medical procedures requiring a clear intestinal tract. Magnesium citrate is available over-the-counter as a liquid or tablet form,also used in the pill form as a magnesium dietary supplement.

Drug Type

Small molecule drug

Synonyms

Magnesium citrate (JAN/USP), Magnesium citrate (RMJ Holdings), Magnesium dicitrate

+ [6]

Target-

Mechanism-

Therapeutic Areas

Other DiseasesCardiovascular Diseases

Active Indication

Intestinal preparationEssential HypertensionHypertension

Inactive Indication-

Originator Organization

RMJ Holdings, Inc.

Active Organization

Horii Pharmaceutical Ind., LTD.RMJ Holdings, Inc.RMJ SGRpA

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (28 Apr 1973),

Intestinal preparation

Regulation-

Login to view timeline

Structure

Molecular FormulaC6H8MgO7

InChIKeyROYPGAQNKYWYDI-UHFFFAOYSA-N

CAS Registry3344-18-1

View All Structures (2)

Author: Miyazaki, Haruka ; Fujisawa, Mizuho ; Takao, Madoka ; Kodama, Yuzo ; Takayama, Hiroshi ; Kinoshita, Masato ; Ueda, Chise ; Ikezawa, Nobuaki ; Toyonaga, Takashi ; Yoshizaki, Tetsuya ; Hori, Hitomi ; Hoki, Shinya ; Sakaguchi, Hiroya ; Morita, Yoshinori ; Abe, Hirofumi ; Ooi, Makoto ; Ishida, Ryosuke ; Okamoto, Norihiro ; Tanabe, Hiroshi ; Tanaka, Shinwa

AbstractBackground and AimSodium picosulfate plus magnesium citrate (SP + MC) is a well‐tolerated bowel preparation agent. However, Japan currently approves only two methods of taking SP + MC: the day‐before and split‐dose preparation, without approval of same‐day preparations. This study aimed to evaluate the efficacy and safety of same‐day SP + MC preparations.MethodsThis was a multicenter, single‐arm, nonrandomized, open‐label study. We enrolled 145 Japanese patients between June and December 2023. The patients received two sachets of SP + MC dissolved in 300 ml of water and 1200 mL or more of clear liquid on the day of colonoscopy. Bowel cleansing efficacy, adverse events (AEs), and patient satisfaction were evaluated.ResultsOf the enrolled patients, 137 underwent colonoscopy according to our protocol. Bowel preparation was adequate in 133 patients (97.1%). The mean total Boston Bowel Preparation Score was 8.3 ± 1.2. Five patients experienced AEs (3.6%): two (1.5%), abdominal pain; one (0.73%), ischemic enteritis; one (0.73%), vomiting or nausea; and one (0.73%), headache. All AEs were treated conservatively. None of the patients exhibited abnormal blood test results or clinical symptoms after receiving SP + MC. Regarding patient satisfaction, all patients were able to take SP + MC as directed; 136 (99.2%) expressed a preference for this bowel preparation for future colonoscopies.ConclusionThe same‐day SP + MC preparation showed high bowel‐cleansing efficacy and satisfaction in Japanese patients without serious AEs.

01 Oct 2024·Therapeutic Apheresis and Dialysis

Factors affecting clinical outcomes of continuous and intermittent plasmapheresis in patients with severe hypertriglyceridemia

Article

Author: Hussein, Eiman A.

AbstractIntroductionAcute hypertriglyceridemia is considered a category III indication for plasmapheresis. The use of plasma as replacement fluid (RF) has been suggested to replace the consumed lipoprotein lipase. Heparin when used as an anticoagulant could possibly release lipoprotein lipase, thereby increasing triglyceride clearance.MethodsThe impact of RF (albumin vs fresh frozen plasma (FFP) and anticoagulant (ACD‐A vs. heparin) on triglycerides following plasmapheresis in 27 patients with severe hypertriglyceridemia (SHTG) was investigated. A paired study of four patients with recurrent SHTG was conducted, evaluating continuous (Optia) versus intermittent flow plasmapheresis (Haemonetics).ResultsShorter procedures positively impacted triglycerides (TG) drop post‐sessions p < 0.05. In albumin sessions, patients who used heparin demonstrated significantly greater drop in TG and required less sessions than did those with citrate p < 0.05. In heparin sessions, patients who used albumin demonstrated significantly greater drop in triglycerides and required less sessions than did those with FFP p < 0.05. Three of six patients who used FFP and heparin showed a triglyceride drop of 11.7% following three sessions and a 50% drop with one albumin session. Compared with Haemonetics, Optia removed comparable volumes of plasma in less time, processing smaller blood volumes and using less citrate p < 0.05. Patients demonstrated significantly lower drop in TG and required more sessions with Haemonetics than they did with Optia p < 0.05.ConclusionShorter procedure was the main predictor for effective TG clearance. This can be achieved by continuous apheresis technology, particularly when using albumin as RF. TG removal via Optia seems to be optimized by using heparin.

01 Sep 2024·Advanced Healthcare Materials

Metabolic Control During Macrophage Polarization by a Citrate‐Functionalized Scaffold for Maintaining Bone Homeostasis

Article

Author: Hong, Chuhang ; Wei, Wenying ; Xia, Yuhao ; Wu, Xiaopei ; Dai, Honglian ; Zhao, Yanan ; Zheng, Dian

AbstractMetabolites, as markers of phenotype at the molecular level, can regulate the function of DNA, RNA, and proteins through chemical modifications or interactions with large molecules. Citrate is an important metabolite that affects macrophage polarization and osteoporotic bone function. Therefore, a better understanding of the precise effect of citrate on macrophage polarization may provide an effective alternative strategy to reverse osteoporotic bone metabolism. In this study, a citrate functional scaffold to control the metabolic pathway during macrophage polarization based on the metabolic differences between pro‐inflammatory and anti‐inflammatory phenotypes for maintaining bone homeostasis, is fabricated. Mechanistically, only outside M1 macrophages are accumulated high concentrations of citrate, in contrast, M2 macrophages consume massive citrate. Therefore, citrate‐functionalized scaffolds exert more sensitive inhibitory effects on metabolic enzyme activity during M1 macrophage polarization than M2 macrophage polarization. Citrate can block glycolysis‐related enzymes by occupying the binding‐site and ensure sufficient metabolic flux in the TCA cycle, so as to turn the metabolism of macrophages to oxidative phosphorylation of M2 macrophage, largely maintaining bone homeostasis. These studies indicate that exogenous citrate can realize metabolic control of macrophage polarization for maintaining bone homeostasis in osteoporosis.

100 Deals associated with Magnesium citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D03265	Magnesium citrate	-	DB11110

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Intestinal preparation	JP	Horii Pharmaceutical Ind., LTD.	28 Apr 1973

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Essential Hypertension	Phase 3	JP	RMJ Holdings, Inc.	30 Jan 2022
Hypertension	Phase 2	-	RMJ SGRpA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02977286 (CTgov)	Phase 4	Constipation	12	Polyethylene Glycols+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Naloxegol Oral Tablet+Methylnaltrexone (Naloxegol Oral Tablet)	apmnbhtllq(mnakzctuyc) = vczfxesqjw broqsmblns (gxquckuuod, kipoducbkf - aqovwdxwib) View more	-	16 Feb 2023
NCT02977286 (CTgov)	Phase 4	Constipation	12	Placebo Oral Tablet+Magnesium Citrate Oral Liquid Product+Bisacodyl 10 mg Suppository+Docusate Sodium 100 Mg oral capsule [Colace]+Senna 217 Mg Oral Tablet+Methylnaltrexone (Placebo Oral Tablet)	apmnbhtllq(mnakzctuyc) = vnvhbekqak broqsmblns (gxquckuuod, zmcovexowa - pdrnvhwjat) View more	-	16 Feb 2023
WCN2015	Not Applicable	Diabetes Mellitus, Type 2	100	Magnesium dicitrate	qwuoxfolhk(tnyfdtxoqu) = ajrcxdynir ubrzgeaikq (bketjiiicn )	-	15 Oct 2015